Barclays PLC Acquires 154,436 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Barclays PLC boosted its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 391.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 193,873 shares of the biopharmaceutical company’s stock after acquiring an additional 154,436 shares during the quarter. Barclays PLC owned 0.08% of Lexicon Pharmaceuticals worth $304,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in LXRX. FMR LLC raised its stake in Lexicon Pharmaceuticals by 28.9% during the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after acquiring an additional 11,179,919 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Lexicon Pharmaceuticals by 4.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock worth $2,225,000 after purchasing an additional 58,147 shares in the last quarter. Nantahala Capital Management LLC bought a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at about $3,871,000. XTX Topco Ltd acquired a new position in Lexicon Pharmaceuticals in the third quarter valued at about $126,000. Finally, Point72 Asset Management L.P. grew its stake in Lexicon Pharmaceuticals by 605.2% during the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock worth $6,924,000 after buying an additional 3,536,805 shares during the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Price Performance

LXRX opened at $0.69 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The stock has a market capitalization of $169.91 million, a P/E ratio of -0.92 and a beta of 1.06. The company’s 50 day simple moving average is $0.81 and its 200-day simple moving average is $1.42. Lexicon Pharmaceuticals, Inc. has a one year low of $0.62 and a one year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The firm had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. During the same quarter in the previous year, the business posted ($0.21) earnings per share. Sell-side analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LXRX has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average price target of $6.00.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.